These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 30907095

  • 1. Effect of Vitamin D Supplementation on Bone Turnover Markers During HIV Pre-Exposure Prophylaxis Using Tenofovir Disoproxil Fumarate-Emtricitabine in Men Who Have Sex with Men.
    Nanayakkara DD, Sun X, Morris S, Louie S, Mulligan K, Overton T, Asante I, Corado K, Jain S, Dubé MP.
    AIDS Res Hum Retroviruses; 2019 Jul; 35(7):608-614. PubMed ID: 30907095
    [Abstract] [Full Text] [Related]

  • 2. Effects of vitamin D and calcium supplementation on bone mineral density among Thai youth using daily HIV pre-exposure prophylaxis.
    Pornpaisalsakul K, Songtaweesin WN, Tepmongkol S, Wongharn P, Kawichai S, Suponsilchai V, Anugulruengkitt S, Puthanakit T, CE-PID - IHRI Adolescent Study Team.
    J Int AIDS Soc; 2020 Oct; 23(10):e25624. PubMed ID: 33040465
    [Abstract] [Full Text] [Related]

  • 3. Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.
    Havens PL, Stephensen CB, Van Loan MD, Schuster GU, Woodhouse LR, Flynn PM, Gordon CM, Pan CG, Rutledge B, Liu N, Wilson CM, Hazra R, Hosek SG, Anderson PL, Seifert SM, Kapogiannis BG, Mulligan K, Adolescent Medicine Trials Network for HIV/AIDS Interventions 117 study team.
    Clin Infect Dis; 2017 Feb 01; 64(3):317-325. PubMed ID: 28013265
    [Abstract] [Full Text] [Related]

  • 4. Short Communication: Association of Vitamin D Insufficiency and Protective Tenofovir Diphosphate Concentrations with Bone Toxicity in Adolescent Boys and Young Men Using Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Pre-Exposure Prophylaxis.
    Havens PL, Tamhane A, Stephensen CB, Schuster GU, Gordon CM, Liu N, Wilson CM, Hosek SG, Anderson PL, Kapogiannis BG, Mulligan K.
    AIDS Res Hum Retroviruses; 2019 Feb 01; 35(2):123-128. PubMed ID: 30280906
    [Abstract] [Full Text] [Related]

  • 5. Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks.
    Tebas P, Kumar P, Hicks C, Granier C, Wynne B, Min S, Pappa K.
    AIDS; 2015 Nov 28; 29(18):2459-64. PubMed ID: 26355674
    [Abstract] [Full Text] [Related]

  • 6. Reversibility of Glomerular Renal Function Decline in HIV-Uninfected Men and Women Discontinuing Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis.
    Mugwanya KK, Wyatt C, Celum C, Donnell D, Kiarie J, Ronald A, Baeten JM, Partners PrEP Study Team.
    J Acquir Immune Defic Syndr; 2016 Apr 01; 71(4):374-80. PubMed ID: 26914909
    [Abstract] [Full Text] [Related]

  • 7. The Safety of Tenofovir-Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B.
    Solomon MM, Schechter M, Liu AY, McMahan VM, Guanira JV, Hance RJ, Chariyalertsak S, Mayer KH, Grant RM, iPrEx Study Team.
    J Acquir Immune Defic Syndr; 2016 Mar 01; 71(3):281-6. PubMed ID: 26413853
    [Abstract] [Full Text] [Related]

  • 8. Plasma Tenofovir Levels to Support Adherence to TDF/FTC Preexposure Prophylaxis for HIV Prevention in MSM in Los Angeles, California.
    Landovitz RJ, Beymer M, Kofron R, Amico KR, Psaros C, Bushman L, Anderson PL, Flynn R, Lee DP, Bolan RK, Jordan WC, Tseng CH, Dierst-Davies R, Rooney J, Wohl AR.
    J Acquir Immune Defic Syndr; 2017 Dec 15; 76(5):501-511. PubMed ID: 28902074
    [Abstract] [Full Text] [Related]

  • 9. Tenofovir disoproxil fumarate appears to disrupt the relationship of vitamin D and parathyroid hormone.
    Havens PL, Long D, Schuster GU, Gordon CM, Price G, Wilson CM, Kapogiannis BG, Mulligan K, Stephensen CB, Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 117 and 109 study teams.
    Antivir Ther; 2018 Dec 15; 23(7):623-628. PubMed ID: 30260797
    [Abstract] [Full Text] [Related]

  • 10. Impact of switching from zidovudine to tenofovir disoproxil fumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients; a substudy of the PREPARE study.
    Cotter AG, Vrouenraets SM, Brady JJ, Wit FW, Fux CA, Furrer H, Brinkman K, Sabin CA, Reiss P, Mallon PW, PREPARE (Preventing Progression of Adipose Tissue Redistribution) Investigators.
    J Clin Endocrinol Metab; 2013 Apr 15; 98(4):1659-66. PubMed ID: 23436922
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.
    Grinsztejn B, Hoagland B, Moreira RI, Kallas EG, Madruga JV, Goulart S, Leite IC, Freitas L, Martins LMS, Torres TS, Vasconcelos R, De Boni RB, Anderson PL, Liu A, Luz PM, Veloso VG, PrEP Brasil Study Team.
    Lancet HIV; 2018 Mar 15; 5(3):e136-e145. PubMed ID: 29467098
    [Abstract] [Full Text] [Related]

  • 14. Review of Real-World Implementation Data on Emtricitabine-Tenofovir Disoproxil Fumarate as HIV Pre-exposure Prophylaxis in the United States.
    Adams JL, Shelley K, Nicol MR.
    Pharmacotherapy; 2019 Apr 15; 39(4):486-500. PubMed ID: 30815960
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Performance of HIV pre-exposure prophylaxis indirect adherence measures among men who have sex with men and transgender women: Results from the PrEP Brasil Study.
    Marins LMS, Torres TS, Leite IDC, Moreira RI, Luz PM, Hoagland B, Kallas EG, Madruga JV, Liu AY, Anderson PL, Grinsztejn B, Veloso VG.
    PLoS One; 2019 Apr 15; 14(8):e0221281. PubMed ID: 31430318
    [Abstract] [Full Text] [Related]

  • 17. Pre-exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Kidney Tubular Dysfunction in HIV-Uninfected Individuals.
    Jotwani V, Scherzer R, Glidden DV, Mehrotra M, Defechereux P, Liu A, Gandhi M, Bennett M, Coca SG, Parikh CR, Grant RM, Shlipak MG.
    J Acquir Immune Defic Syndr; 2018 Jun 01; 78(2):169-174. PubMed ID: 29767638
    [Abstract] [Full Text] [Related]

  • 18. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.
    Deutsch MB, Glidden DV, Sevelius J, Keatley J, McMahan V, Guanira J, Kallas EG, Chariyalertsak S, Grant RM, iPrEx investigators.
    Lancet HIV; 2015 Dec 01; 2(12):e512-9. PubMed ID: 26614965
    [Abstract] [Full Text] [Related]

  • 19. Impact of Tenofovir-Based Pre-exposure Prophylaxis on Biomarkers of Bone Formation, Bone Resorption, and Bone Mineral Metabolism in HIV-Negative Adults.
    Nickolas TL, Yin MT, Hong T, Mugwanya KK, Branch AD, Heffron R, Ramalho J, Nandakumar R, Dworakowski E, Wanga V, Mugo NR, Ronald A, Celum C, Donnell D, Baeten JM, Wyatt CM, Partners PrEP Study Team .
    Open Forum Infect Dis; 2019 Oct 01; 6(10):ofz338. PubMed ID: 31660332
    [Abstract] [Full Text] [Related]

  • 20. Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis.
    Glidden DV, Mulligan K, McMahan V, Anderson PL, Guanira J, Chariyalertsak S, Buchbinder SP, Bekker LG, Schechter M, Grinsztejn B, Grant RM.
    J Acquir Immune Defic Syndr; 2017 Oct 01; 76(2):177-182. PubMed ID: 28639995
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.